Jiangsu Nhwa Pharmaceutical Co., LTD: history, ownership, mission, how it works & makes money

From its founding in 1978 as a specialist in central nervous system medicines to its public listing as 002262.SZ in 2008, Jiangsu Nhwa Pharmaceutical has scaled into a focused innovator with three GMP production bases covering over 800 acres and more than 10 production lines, a national-level R&D center and partnerships-such as with the National Academy of Military Medical Sciences on Iptakalim-that underpin its unique product mix spanning anesthesiology, psychiatry, neurology and expanding cardiovascular offerings; the company reports a market capitalization of about 24.90 billion CNY (Dec 2025), a daily trading volume above 4 million shares, an EPS of 1.21 CNY (TTM) and a May 2025 cash dividend of 0.36 CNY per share, while financially it posted revenue of 5.70 billion CNY in 2024 (up 13.01% year-over-year), quarterly revenue of 1.46 billion CNY for Q3 2025 (up 5.70% YoY) and net income of 1.11 billion CNY for the nine months to Sept 30, 2025 (up 8.42% YoY), driven by a business model that monetizes proprietary CNS portfolios, licensing and broader market distribution through domestic and international channels supported by robust supply-chain and GMP-compliant manufacturing-and with sustained investment in innovation, allocating approximately 15% of revenues to R&D, Nhwa's blend of targeted therapeutic focus, recognized quality credentials (national high-tech enterprise, ISO14000, IP demonstration unit) and active shareholder returns paint a picture of a company leveraging specialization, scale and research to capture value in the evolving pharmaceutical market

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ): Intro

• Founding year: 1978; Shenzhen Stock Exchange listing: 2008 (stock code 002262)
• Core therapeutic focus: CNS (anesthesiology, psychiatry, neurology)
• Cardiovascular portfolio highlight: Iptakalim - an innovative antihypertensive with a distinct chemical scaffold and mechanism
• Manufacturing footprint: three large-scale GMP production bases covering over 800 acres in total
• Recognitions: designated as a national high-tech enterprise and ranked among China's top-100 pharmaceutical companies

• 1978-1999: Establishment and CNS specialization - early R&D and manufacturing focused on central nervous system drugs, building technical depth in anesthesiology and psychiatry agents.
• 2000-2007: Product-line consolidation - expansion of CNS product family and domestic market penetration.
• 2008: IPO - listed on Shenzhen Stock Exchange (002262.SZ), enabling broader capital access for R&D and capacity expansion.
• 2010s: Diversification - development and commercialization of Iptakalim for hypertension and entry into cardiovascular therapeutics; construction of additional GMP production sites.
• 2020s: Scale and recognition - three GMP bases operational, national high-tech enterprise status, ongoing filings and registrations for expanded indications and formulations.

• R&D: Discovery and development centered on CNS molecular entities and later cardiovascular candidates (notably Iptakalim); clinical development, formulation, and regulatory submissions.
• Manufacturing: In-house GMP facilities (three bases) enabling API and finished-dose production, scale-up, and contract manufacturing opportunities.
• Commercialization: Domestic hospital and retail pharmacy channels for prescription CNS and cardiovascular products; selected exports and licensing deals.
• Revenue streams: Product sales (primary), licensing/royalties, contract manufacturing, and government/industry R&D grants.

• CNS portfolio: multiple anesthetics, psychotropics, and neurology agents marketed domestically with established hospital channels.
• Iptakalim: flagship cardiovascular candidate - distinctive mechanism targeting ATP-sensitive potassium (KATP) channels (chemical innovation differentiating it from typical antihypertensives).
• Pipeline approach: incremental improvements of existing CNS molecules, line extensions (formulation upgrades), and targeted new chemical entity (NCE) programs in cardiovascular and CNS niches.

• Drug sales: core revenue from marketed CNS drugs and cardiovascular products distributed through hospitals, clinics, and pharmacies.
• API and formulation manufacturing: margins from internal cost efficiencies at large GMP sites and third-party contract manufacturing.
• Licensing & collaboration: milestone payments, royalties from out-licensed indications or geographic rights, and co-development agreements.
• R&D funding & grants: supplementary income from government innovation programs and industry partnerships supporting clinical development.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ): History

• Founded and regional manufacturing expansion in Jiangsu province (early stages).
• Public listing on the Shenzhen Stock Exchange under code 002262.
• Product diversification into APIs, generic and branded formulations, and OTC products.
• Increased R&D investment and export market development in the 2010s-2020s.

• Listed entity: Shenzhen Stock Exchange, ticker 002262.SZ.
• Market capitalization: ~24.90 billion CNY (as of December 2025).
• Shareholder base: mix of institutional investors, retail investors, and company insiders.
• Liquidity indicator: daily trading volume >4 million shares.
• EPS (TTM): 1.21 CNY.
• Dividend: cash dividend declared May 2025 of 0.36 CNY per share.

• Develop and deliver affordable, high-quality pharmaceuticals for domestic and international markets.
• Invest in R&D to move up the value chain from APIs to differentiated formulations.
• Maintain compliance and transparency under Chinese securities regulations to support investor confidence.

• Manufacturing and sales of APIs and finished-drug formulations (prescription and OTC): core revenue streams.
• Contract manufacturing and exports: utilize production capacity to supply third parties and overseas distributors.
• R&D-driven pipeline: develop higher-margin branded generics and niche products to improve margins.
• Vertical integration: raw material sourcing, in-house manufacturing, and distribution reduce costs and capture margin across the value chain.
• Capital allocation: dividends (e.g., 0.36 CNY/share in May 2025) and reinvestment into capacity and R&D balance shareholder returns with growth.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ): Ownership Structure

• Mission and values: dedicated to CNS drug R&D and production; committed to improving patient outcomes and reducing suffering.
• R&D intensity: invests approximately 15% of total revenues into research and development, driving multiple therapeutic product launches.
• Quality & recognition: designated a national '20 years 20 star' medical quality management enterprise star unit.
• Environment & IP: ISO 14000 certified; recognized as a national intellectual property demonstration unit.
• Workplace culture: emphasizes a harmonious, employee-friendly environment balancing professional growth and personal life.

• Product sales: marketed proprietary CNS drugs and licensed formulations sold in hospitals, psychiatric clinics and retail pharmacies.
• R&D-driven launches: revenue uplift from new therapeutic approvals funded by persistent reinvestment (~15% of revenues).
• Contract manufacturing and CDMO services: third-party production for peers and partners leveraging certified GMP facilities.
• Licensing and collaborations: out-licensing of IP and co-development agreements for international or regional commercialization.

• High R&D allocation to sustain pipeline growth and defend market share via IP protections.
• Continuous quality compliance and environmental controls to support long-term manufacturing contracts.
• Maintaining employee welfare and corporate culture to retain scientific and manufacturing talent.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ): Mission and Values

• Production footprint: three large-scale GMP production bases covering over 800 acres with more than 10 production lines for tablets, capsules, sterile and non-sterile injections, granules and oral liquids.
• GMP compliance: all manufacturing sites adhere to China GMP (and in applicable product lines, international GMP) standards and operate quality management systems for batch control, stability testing and product release.
• R&D and innovation: a national-level R&D center that functions as a provincial engineering technology research center and hosts a national postdoctoral research station-enabling preclinical research, formulation development, process optimization and scale-up.
• Strategic partnerships: collaborative drug development with leading institutes, notably a development partnership with the National Academy of Military Medical Sciences on Iptakalim (an innovative anti-hypertension candidate), illustrating a pathway from licensed in-licensing/co-development to commercialization.
• Supply chain & procurement: centralized sourcing of API and excipients combined with regional warehousing and logistics to ensure continuity of raw-material supply and timely nationwide distribution.
• Commercial reach: a comprehensive marketing and sales network covering hospital channels, retail pharmacies and export markets; sales force and distributor partnerships drive product access across China and selected overseas markets.

• Finished-dosage manufacturing: revenue from sale of branded generics and proprietary formulations produced in-house across multiple dosage forms.
• Contract manufacturing: toll-manufacturing and third-party production services leveraging excess capacity on production lines.
• R&D-driven product pipeline: monetization via new drug approvals, license-in/out deals and co-development income (milestone and royalty structures for partnered products such as Iptakalim).
• Domestic hospital and retail sales: direct sales to hospital formularies and distribution through pharmacy chains and wholesalers.
• Export sales: sales to overseas markets via export registrations and partnerships with foreign distributors-adding foreign-currency revenue streams.

• In-house capabilities: formulation development, analytical method development, GMP process validation and stability studies conducted at the national-level R&D center.
• Advanced programs: cardiovascular/metabolic therapeutic development (Iptakalim collaboration), generic product line extensions and specialty sterile injectables.
• Talent & infrastructure: postdoctoral station supports advanced scientific staff hiring and high-level research output feeding the product pipeline and process improvements.

• Domestic channels: direct hospital tenders, provincial distributors, retail pharmacy networks and e-channels for over-the-counter products.
• International reach: exported products through regulatory filings and partner distributors in targeted markets; export strategy leverages production scale and GMP compliance.
• Commercial organization: regional sales teams supported by medical affairs and tendering specialists to secure hospital listings and maintain market share.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ): How It Works

• Core therapeutic focus: CNS drugs - anesthesiology, psychiatry, neurology (majority of product portfolio and revenue).
• Growth diversification: cardiovascular market entry driven by Iptakalim development and commercialization.
• Revenue mix: finished dosage forms (tablets/injections), API supply for partner firms, and proprietary specialty formulations.
• Channels: hospital tendering, institutional procurement, retail pharmacies, and limited international exports.

• R&D pipeline: central R&D units develop next-generation CNS molecules and cardiovascular candidates; clinical-stage projects are prioritized for domestic registration and hospital inclusion.
• Manufacturing footprint: GMP-compliant facilities for sterile injectables and solid oral dosages; vertically integrated API production reduces input cost volatility.
• Regulatory/commercial pathway: product registration with NMPA (China), hospital catalog listing via tender wins, and scale-up of salesforce for psychiatry/neurology specialties.
• Partnerships & licensing: co-development and out-licensing of selected compounds, contract manufacturing agreements to monetize excess capacity.

• Sales of CNS therapeutics (major share): anesthetics, antipsychotics, anticonvulsants, other neurology drugs.
• Sales of cardiovascular drug Iptakalim following commercialization-adds diversification and new hospital account penetration.
• API and CMO (contract manufacturing) services to regional pharma partners.
• Sales-based and milestone-based revenue from licensing deals and co-development partnerships.

• Gross margin drivers: higher-margin proprietary CNS formulations and controlled API costs via integrated manufacturing.
• Operating leverage: scale in hospital tenders and repeat prescription volumes lift margins as fixed manufacturing and R&D costs are absorbed.
• R&D spend: targeted investment in CNS and cardiovascular candidates aimed at indiciated long-term revenue uplift; selective external collaborations to spread risk.
• Cash flow profile: operating cash conversion supported by steady hospital receivables and recurring sales of long-established CNS products.

• Hospital-focused salesforce for anesthesia and neurology departments; tender-driven pricing discipline.
• Formulary and guideline engagement to drive prescription uptake of Iptakalim and key CNS drugs.
• Lifecycle management: line extensions, sustained-release formulations, and pediatric/adult indications to broaden market reach.
• Selective export strategy to neighboring markets and contract manufacturing export orders to utilize excess capacity.

Jiangsu Nhwa Pharmaceutical Co., LTD (002262.SZ): How It Makes Money

• Prescription pharmaceuticals sales: branded CNS products (core legacy portfolio) sold through hospital channels, pharmacies and institutional tenders.
• New product launches: commercialization of cardiovascular candidates (notably Iptakalim) and other pipeline assets aimed at large chronic-disease markets.
• OEM/contract manufacturing and API supply to domestic and international partners.
• Export sales and licensing partnerships with overseas distributors-supported by attendance at global trade shows and distributor agreements.
• R&D collaborations and milestone/licensing payments from co-development deals.

• Only Chinese listed company with an exclusive, deep focus on CNS therapeutics historically-this niche focus has yielded strong market recognition and clinical expertise in neuropsychiatric medicines.
• Expanding into hypertension/cardiovascular space with Iptakalim positions the company to access the global hypertension market, valued in the tens of billions USD annually.
• Active participation in international trade shows and partnerships improves global channel access and supports export growth.
• Investment in R&D and quality/environmental systems aligns the company with international regulatory and buyer expectations, aiding tender wins and cross-border sales.

• Pipeline commercialization: converting late-stage assets (e.g., Iptakalim) into scale sales to capture hypertension market growth.
• Geographic expansion: targeted marketing and distributor partnerships adapted for demographic and clinical differences in export markets.
• R&D-led differentiation: continued allocation of ~8-12% of revenue to R&D to sustain novel product introductions and lifecycle extensions.
• Sustainability & quality: adherence to international GMP, ISO and environmental practices to facilitate cross-border regulatory acceptance and tender eligibility.
• Operational scale: leveraging contract manufacturing and API sales to smooth revenue streams and improve capacity utilization.